Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics

2 型糖尿病：了解其早期驱动因素和治疗之路

• 批准号: 10682747
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.32万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-05 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10682747
• 关键词: Abate; Address; Affect; Basic Science; Beta Cell; Career Mobility; Classification; Collaborations; Communication; Complications of Diabetes Mellitus; Development; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; Education; Educational workshop; Event; Failure; Future; Glucose; Glycosylated hemoglobin A; Growth; Homeostasis; Industrialization; Insulin Resistance; Intervention; Knowledge; Learning; Legal patent; Life; Measures; Metabolic; Metabolic Diseases; Methodology; Molecular; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Organ; Outcome; Participant; Pathogenesis; Pathway interactions; Patients; Research; Research Personnel; Retinal Diseases; Scientist; Structure of beta Cell of islet; Technology; Therapeutic; Thinking; Time; Translational Research; Treatment outcome; Vision; Work; career; clinical practice; comorbidity; design; diabetes mellitus therapy; diabetes pathogenesis; improved; insight; interest; mortality; multidisciplinary; next generation; novel; off-patent; posters; precision medicine; prevent; symposium; therapeutically effective; treatment and outcome

ABSTRACT Support is requested for a Keystone Symposia conference entitled Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, organized by Drs. Christopher Rhodes, Lora Heisler, and Martin Myers. The conference will be held in Palm Springs, CA from May 1 - 4, 2023. Early detection and consequential intervention are key to good treatment outcomes and avoidance of complications for most diseases. Arguably, this may not be the case for Type-2 diabetes (T2D) where measures of elevated glucose and HbA1C, historically related to a predicted onset of retinopathy, occur too late in the pathogenesis of the disease. This makes the need for improved markers of T2D necessary to better diagnose and treat this prevalent disease at early stages. With the advent of precision medicine, now is the time to re-examine the pathogenesis of type 2 (pre)diabetes at the molecular level. However, questions the field remain, such as: 1. Which subsets of T2D define the rate of progression to certain diabetes complications; 2. Can early molecular drivers of the disease be better identified; 3. What factors contribute to dysfunctional inter-organ communication and altered metabolic homeostasis; 4. Does pancreatic ß-cell failure really define the disease; and 5. If detected early enough, can we envision ways to reverse, or even prevent T2D? The silver lining is that with several commonly used T2D therapies coming off patent soon, this may just be conceivable. Nonetheless, there also remains a need for more effective therapeutic approaches, not just for T2D, but also for its comorbidities. Therefore, this Keystone Symposia conference will examine the current knowledge of T2D pathogenesis and the therapeutic landscape with a vision towards earlier diagnosis, as well as, towards more effective and tailored T2D treatment regime(s) that could also prevent (or significantly delay) the pathway to complications and comorbidities.

摘要